Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types.

Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types.
复制标题

DOI:
10.1001/jamahealthforum.2021.4205
复制
发表时间:
2021-12
期刊:
JAMA health forum
影响因子:
--
通讯作者:
Estrella MM
Estrella MM
中科院分区:
其他
文献类型:
--
作者:
Tummalapalli SL;Montealegre JL;Warnock N;Green M;Ibrahim SA;Estrella MM

文献摘要

参考文献

被引文献

相似文献

这项横断面研究评价了商业、健康保险交换、退伍军人事务部、医疗保险、医疗补助或其他保险对卡格列净、达格列净、恩格列净和厄图格列净的承保规定。
This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
DOI: 10.1001/jamanetworkopen.2021.6139
发表时间: 2021-04-01
期刊: JAMA network open
影响因子: 13.8
作者:
Eberly LA;Yang L;Eneanya ND;Essien U;Julien H;Nathan AS;Khatana SAM;Dayoub EJ;Fanaroff AC;Giri J;Groeneveld PW;Adusumalli S
通讯作者: Adusumalli S
DOI: 10.1111/dom.14162
发表时间: 2020-09-02
影响因子: 5.8
作者:
McEwan, Phil;Bennett, Hayley;Kosiborod, Mikhail
通讯作者: Kosiborod, Mikhail
DOI: 10.1001/jamanetworkopen.2020.20969
发表时间: 2020-10-01
期刊: JAMA network open
影响因子: 13.8
作者:
Luo J;Feldman R;Rothenberger SD;Hernandez I;Gellad WF
通讯作者: Gellad WF